X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs CIPLA - Comparison Results

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA CIPLA PLETHICO PHARMA/
CIPLA
 
P/E (TTM) x -1.1 46.0 - View Chart
P/BV x 0.0 3.8 0.4% View Chart
Dividend Yield % 0.0 0.3 -  

Financials

 PLETHICO PHARMA   CIPLA
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
CIPLA
Mar-17
PLETHICO PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs395622 63.5%   
Low Rs31458 6.8%   
Sales per share (Unadj.) Rs604.4181.9 332.4%  
Earnings per share (Unadj.) Rs32.512.9 252.4%  
Cash flow per share (Unadj.) Rs51.329.3 175.1%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs473.6155.7 304.2%  
Shares outstanding (eoy) m34.08804.51 4.2%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.43.0 11.9%   
Avg P/E ratio x6.642.0 15.6%  
P/CF ratio (eoy) x4.218.4 22.5%  
Price / Book Value ratio x0.53.5 13.0%  
Dividend payout %015.5 0.0%   
Avg Mkt Cap Rs m7,262434,516 1.7%   
No. of employees `000NA23.0 0.0%   
Total wages/salary Rs m1,59626,338 6.1%   
Avg. sales/employee Rs ThNM6,349.1-  
Avg. wages/employee Rs ThNM1,143.0-  
Avg. net profit/employee Rs ThNM449.3-  
INCOME DATA
Net Sales Rs m20,598146,302 14.1%  
Other income Rs m3862,287 16.9%   
Total revenues Rs m20,984148,589 14.1%   
Gross profit Rs m2,81824,758 11.4%  
Depreciation Rs m64213,229 4.9%   
Interest Rs m1,5931,594 100.0%   
Profit before tax Rs m96912,222 7.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-70 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1381,798 -7.7%   
Profit after tax Rs m1,10710,354 10.7%  
Gross profit margin %13.716.9 80.8%  
Effective tax rate %-14.314.7 -97.1%   
Net profit margin %5.47.1 75.9%  
BALANCE SHEET DATA
Current assets Rs m18,87787,370 21.6%   
Current liabilities Rs m11,89633,081 36.0%   
Net working cap to sales %33.937.1 91.3%  
Current ratio x1.62.6 60.1%  
Inventory Days Days3687 41.3%  
Debtors Days Days19862 317.5%  
Net fixed assets Rs m9,861111,567 8.8%   
Share capital Rs m3411,609 21.2%   
"Free" reserves Rs m12,331123,645 10.0%   
Net worth Rs m16,139125,254 12.9%   
Long term debt Rs m4,70636,454 12.9%   
Total assets Rs m33,146209,532 15.8%  
Interest coverage x1.68.7 18.5%   
Debt to equity ratio x0.30.3 100.2%  
Sales to assets ratio x0.60.7 89.0%   
Return on assets %8.15.7 142.9%  
Return on equity %6.98.3 83.0%  
Return on capital %12.38.5 144.6%  
Exports to sales %21.434.2 62.5%   
Imports to sales %15.28.3 182.5%   
Exports (fob) Rs m4,40250,050 8.8%   
Imports (cif) Rs m3,13612,203 25.7%   
Fx inflow Rs m4,40251,066 8.6%   
Fx outflow Rs m3,18417,678 18.0%   
Net fx Rs m1,21933,388 3.6%   
CASH FLOW
From Operations Rs m2,43723,824 10.2%  
From Investments Rs m-6,265-13,127 47.7%  
From Financial Activity Rs m2,490-13,239 -18.8%  
Net Cashflow Rs m-1,337-2,478 54.0%  

Share Holding

Indian Promoters % 82.7 16.0 516.9%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 4.3 12.2 35.2%  
FIIs % 5.5 23.7 23.2%  
ADR/GDR % 0.0 1.1 -  
Free float % 7.5 26.2 28.6%  
Shareholders   10,665 161,166 6.6%  
Pledged promoter(s) holding % 85.7 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   CADILA HEALTHCARE  TTK HEALTHCARE  SHASUN PHARMA  DISHMAN PHARMA  J.B.CHEMICALS  

Compare PLETHICO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Strong Note; Tata Global Beverages Surges 8.3%(Closing)

Indian share markets snapped their losing streak of last week and finished the trading day on a strong note due to strong buying momentum in FMCG stocks, metal stocks and auto stocks.

Related Views on News

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

Sep 19, 2016

Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

Aug 4, 2017

The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA 5-YR ANALYSIS

COMPARE PLETHICO PHARMA WITH

MARKET STATS